SCHEDULE: Investor Group Reduces Stake in Ikena Oncology, No Longer 5% Holder

BML Investment Partners and Braden M. Leonard have significantly reduced their beneficial ownership in Ikena Oncology, Inc., ceasing to be a 5% holder after recent share sales.

Summary

• BML Investment Partners, L.P. and Braden M. Leonard filed an Amendment No. 1 to Schedule 13D regarding their beneficial ownership in Ikena Oncology, Inc.
• BML Investment Partners, L.P. now beneficially owns 215,832 shares of Common Stock, representing 1.9% of the class.
• Braden M. Leonard beneficially owns an aggregate of 220,832 shares, also representing 1.9% of the class, which includes the shares held by BML Investment Partners, L.P.
• The shares were acquired for investment purposes using working capital: $4.3 million by BML Investment Partners, L.P. and $94,800 by Braden M. Leonard.
• The reporting persons are no longer a 5% holder of Ikena Oncology, Inc. following the completion of a transaction with Inmagene on July 25, 2025.
• Recent sales by BML Investment Partners, L.P. occurred between July 16, 2025, and July 22, 2025, with prices ranging from $1.20 to $1.30 per share.

Sentiment

Score: 4

Explanation: The filing indicates a significant reduction in stake by a previously major investor, which can be interpreted as a negative signal regarding their confidence in the company's short-term prospects or valuation, although it's framed as an 'ordinary course of business' investment decision.

Negatives

• A significant investor group, BML Investment Partners, L.P. and Braden M. Leonard, has reduced its stake in Ikena Oncology, Inc. and is no longer a 5% beneficial owner, which could be perceived as a negative signal by the market.

Future Outlook

The reporting persons have no present plans or proposals that relate to or would result in any of the actions described in Item 4(a) through (j) of Schedule 13D. They may, however, evaluate their investment on a continuing basis and may, from time to time, acquire or dispose of Common Stock of the Issuer based on factors such as price, availability, business prospects, investment policies, market conditions, and tax considerations.

Stakeholder Impact

• Shareholders may view the reduction in stake by a significant investor as a negative signal, potentially impacting the company's share price due to perceived decreased investor confidence.

Next Steps

• Reporting persons may continue to evaluate their investment in Ikena Oncology, Inc. and potentially acquire or dispose of shares in the future.

Key Dates

Recommendation

While a significant investor has reduced their stake, the filing itself does not provide enough information about the company's fundamentals or future prospects to warrant a strong buy or sell recommendation. The divestment could be due to portfolio rebalancing rather than a fundamental negative view of the company. Investors should hold and await further company-specific news or financial reports.

Keywords

Ikena Oncology, IKNA, BML Investment Partners, Braden M. Leonard, Schedule 13D, beneficial ownership, stock sales, investment, biotechnology, pharmaceuticals